When an older adult with atrial fibrillation, or Afib, stops taking an anticoagulant, it raises their risk of stroke or heart attack more than risks of bleeding, according to a new report published ...

A nursing home in Gibson City received three fines for violations according to the Illinois Department of Public Health, ...

The baseline CHA 2 DS 2-VASc score helped to identify patient with subclinical atrial fibrillation (SCAF) in whom the benefit for reducing the risk of stroke and systemic embolism (SE) with an oral ...

A scientific statement has been published by the AHA regarding obstetric and cardiovascular risk in patients receiving assisted reproductive technology.

Left atrial appendage closure (LAAC) in patients at moderate to high risk for stroke who were undergoing catheter atrial fibrillation (AFib) ablation resulted in significantly less bleeding compared ...

Notwithstanding the substantial progress in acute stroke care over the past 15 years, the focus of stroke medical advances and healthcare resources has been on acute and subacute recovery phases, ...

For decades, unfractionated heparin (hereafter, heparin) has been the primary anticoagulant used for extracorporeal membrane oxygenation (ECMO) support. More recently, however, bivalirudin, a direct ...

In 2008, the NPSGs were updated to include goals regarding OAT. The NPSGs concerning anticoagulation (specifically, NPSG 03.05.01) represent a change in the external environment, or natural experiment ...

An­thos Ther­a­peu­tics’ an­ti­co­ag­u­lant pos­es a low­er risk of bleed­ing events than Bay­er and J&J’s Xarel­to when used to pre­vent blood clots in atri­al fib­ril­la ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Novel agent abelacimab has potential to be a safer anticoagulant, according to the randomized AZALEA-TIMI 71 trial.

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study.

Promising results show that abelacimab could revolutionize anticoagulation therapy by slashing bleeding risks without compromising stroke protection for patients with atrial fibrillation.